SENSORION SA (ALSEN.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALSEN - FR0012596468 - Common Stock
ALSEN.PA Key Statistics, Chart & Performance
The current stock price of ALSEN.PA is 0.322 EUR. In the past month the price decreased by -7.47%. In the past year, price decreased by -53.47%.
ALSEN.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 72.28 | 47.84B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.15B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.42B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 827.38M | ||
| PHIL.MI | PHILOGEN SPA | 20.18 | 672.52M | ||
| IVA.PA | INVENTIVA SA | N/A | 692.44M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M |
Related stock screener links
About ALSEN.PA
Company Profile
Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 68 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
Company Info
SENSORION SA
375, rue du Professeur Joseph Blayac
Montpellier OCCITANIE FR
Employees: 63
Phone: 33467207730
SENSORION SA / ALSEN.PA FAQ
What does SENSORION SA do?
Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 68 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
What is the current price of ALSEN stock?
The current stock price of ALSEN.PA is 0.322 EUR. The price increased by 2.88% in the last trading session.
What is the dividend status of SENSORION SA?
ALSEN.PA does not pay a dividend.
What is the ChartMill rating of SENSORION SA stock?
ALSEN.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ALSEN stock?
SENSORION SA (ALSEN.PA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for ALSEN stock?
SENSORION SA (ALSEN.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).
Who owns SENSORION SA?
You can find the ownership structure of SENSORION SA (ALSEN.PA) on the Ownership tab.
ALSEN.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALSEN.PA. When comparing the yearly performance of all stocks, ALSEN.PA is a bad performer in the overall market: 93.98% of all stocks are doing better.
ALSEN.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALSEN.PA. ALSEN.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALSEN.PA Financial Highlights
Over the last trailing twelve months ALSEN.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 11.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.3% | ||
| ROE | -49.29% | ||
| Debt/Equity | 0.01 |
ALSEN.PA Forecast & Estimates
13 analysts have analysed ALSEN.PA and the average price target is 2.35 EUR. This implies a price increase of 628.57% is expected in the next year compared to the current price of 0.322.
For the next year, analysts expect an EPS growth of 13.89% and a revenue growth 17.4% for ALSEN.PA